Unavailable
Unavailable
Save time and jump to the most important pieces.
TAMPA, FL, Dec. 17, 2024 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (the "Company") (NASDAQ:SCNX), a specialty pharma company with a novel pipeline of brand products, is pleased to announce its participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ. The Company's management team will deliver a corporate presentation and engage in one-on-one meetings with institutional and individual investors to discuss the Company's recent developments, growth strategy, and investment opportunities. About The Microcap Conference 2025 The Micr
COMMACK, NY and TAMPA, FL, Dec. 10, 2024 (GLOBE NEWSWIRE) -- SCIENTURE, LLC ("the "Company"), a wholly owned subsidiary of SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), focused on developing and commercializing novel branded, specialty pharma products, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a new patent, No. 12,156,869 (the ‘869 patent), further strengthening the intellectual property position and coverage for the Company's SCN-102 product. The ‘869 patent is in addition to the previously granted patent for SCN-102 by the USPTO, No. 11,890,273 (the ‘273 patent). The ‘869 patent and the ‘273 patent, both titled, "LOSARTAN LIQUID FORMULATIONS AND METHODS OF U
Scienture Holdings to Receive Funding of Up to $12 Million From Private Placement of 10% Secured Convertible Debentures and Up to $50 Million from Equity Line of Credit Tampa, FL, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Scienture Holdings, Inc. (NASDAQ:SCNX) (the "Company" or "Scienture"), a pharmaceutical company with strategic capabilities across R&D, manufacturing, sales & marketing, and commercial operations, today announced it has entered into a securities purchase agreement to issue 10% secured convertible debentures in an aggregate principal amount of up to $12,222,222 million to certain affiliates of Arena Investors, LP ("Arena") in three separate tranches that are subject to certain cl
8-K - Scienture Holdings, Inc. (0001382574) (Filer)
S-1/A - Scienture Holdings, Inc. (0001382574) (Filer)
8-K - Scienture Holdings, Inc. (0001382574) (Filer)